KFF Health News Sep 12 2025 FDA leaders under President Donald Trump are moving to abandon a decades-old policy of asking outside experts to review drug applications, a move critics say would shield the agency's decisions from public scrutiny. The agency "would like to get away" from assembling panels of experts to examine and vote on individual drugs, because "I don't think they're needed," said George Tidmarsh, head of the FDA's Center for Drug Evaluation and Research. He relayed the message

Tag-uri: Donald Trump